BEERE: a web server for biomedical entity expansion, ranking and explorations

Zongliang Yue¹, Christopher D. Willey², Anita B. Hjelmeland³ and Jake Y. Chen^{1,*}

¹Informatics Institute, School of Medicine, the University of Alabama at Birmingham, AL 35233, USA, ²Department of Radiation Oncology, School of Medicine, the University of Alabama at Birmingham, AL 35233, USA and ³Department of Cell, Developmental and Integrative Biology, School of Medicine, the University of Alabama at Birmingham, AL 35233, USA 35233, USA

Received March 14, 2019; Revised May 04, 2019; Editorial Decision May 06, 2019; Accepted May 20, 2019

ABSTRACT

BEERE (Biomedical Entity Expansion, Ranking and Explorations) is a new web-based data analysis tool to help biomedical researchers characterize any input list of genes/proteins, biomedical terms or their combinations, i.e. 'biomedical entities', in the context of existing literature. Specifically, BEERE first aims to help users examine the credibility of known entity-to-entity associative or semantic relationships supported by database or literature references from the user input of a gene/term list. Then, it will help users uncover the relative importance of each entity—a gene or a term—within the user input by computing the ranking scores of all entities. At last, it will help users hypothesize new gene functions or genotype-phenotype associations by an interactive visual interface of constructed global entity relationship network. The output from BEERE includes: a list of the original entities matched with known relationships in databases; any expanded entities that may be generated from the analysis; the ranks and ranking scores reported with statistical significance for each entity; and an interactive graphical display of the gene or term network within data provenance annotations that link to external data sources. The web server is free and open to all users with no login requirement and can be accessed at http://discovery.informatics.uab.edu/beere/.

INTRODUCTION

Following high-throughput biology experiments, biomedical researchers frequently find themselves asking a repeated question, 'which gene or protein should I test first among dozens or even hundreds of significant genes or proteins determined from the high-throughput biology studies?' Meanwhile, conventional hypothesis-driven researchers, after performing literature studies of a biological research topic, may also find it challenging to follow through a comprehensive list of candidate biological concepts, including genes, diseases, drugs, phenotypic features and clinical attributes, from which they often ask, 'which disease attribute or features should I focus my study on next?' In this work, we are motivated by the need to address the two types of recurring questions mentioned above for biomedical researchers.

To address the first question on how to characterize a list of genes or proteins, bioinformaticians typically implement gene ranking or gene set based enrichment analysis to avoid 'cherry-picking' of genes for subsequent experimental validations (1). High-throughput biological studies using Genome-Wide Association Studies (GWAS) or RNAsequencing have yielded an overwhelming amount of candidate genetic variants and candidate genes for manual examinations, thus presenting opportunities for gene prioritization analysis (2). In the past decade, there have been a limited number of web-based online gene prioritization tools such as PINTA (3), ToppGene (4), SUSPECTS (5), PROSPECTR (6) and ENDEAVOUR (7), but the majority are not web-based (8). These tools work by performing statistical characterizations of genetic linkage patterns, sequence annotations, gene co-expression patterns, proteinprotein network linkage patterns or correlated pathways (9-14). In particular, with the comprehensive accumulation of scored gene-to-gene correlative relationships into knowledgebases such as the STRING database (15) and the HAPPI 2.0 database (16), network-based gene prioritization methods have been shown to have an overall high accuracy and low system-level bias, as long as the threshold may be controlled to balance between network data coverage and data quality (15). Examples of network-based gene prioritization applications include discovering disease genes

© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.

^{*}To whom correspondence should be addressed. Tel: +1 205 996 0738; Email: jakechen@uab.edu

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License

⁽http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

for complex human genetic disorders (8), finding drug targets (17,18) and repositioning drugs (19).

Few existing web-based tools can help researchers address the second question on how to characterize a list of biomedical terms. A major bottleneck is the lack of a comprehensive biomedical term-to-term association knowledge-base until recently (20). Extracting semantic information from the biomedical literature or the clinical databases at the PubMed scale has been challenging for several reasons: a lack of standard ontology and their application to annotate all PubMed sentences (20), a lack of advanced natural language processing techniques that have been tested at scale (21), the limitation for large-scale application that impedes further data analysis (22). Furthermore, there are few available tools to help prioritize biomedical concepts across broad Unified Medical Language System (UMLS) concept categories, except for Phenolyzer that covers two categories only-'diseases' and 'genes' (23). Therefore, to perform general-purpose web-based 'biomedical term prioritizations', new tools must be developed to integrate advanced entity disambiguation techniques (24–27), network-based prioritization techniques and biomedical semantic relationship database repositories (20).

In this paper, we report the development of a new easyto-use web server called Biomedical Entity Expansion, Ranking and Explorations (BEERE). BEERE aims to prioritize user-provided biomedical entities for detailed investigations of the related concepts, known associative relationships among them, supporting literature evidence, their relative significance to one another and the relationship network context in which they reside. BEERE works in two input modes: a gene input mode and a term input mode. In the gene input mode, BEERE can take the input of a list of gene symbols or gene IDs (28), retrieve annotated protein-protein interaction relationships among them with optional gene neighborhood expansions, rank the retrieved genes using entity prioritization methods and construct a gene network for user examinations of highly relevant genes and their relationships to other genes supported by literature references. In the term input mode, BEERE can take the input of a list of concept terms as words/phrases or as Concept Unique Identifiers (CUIs) (29), retrieve annotated term-to-term semantic relationships among them with optional term neighborhood expansions, rank the retrieved terms using entity prioritization methods and construct a concept term network for user examinations of highly relevant terms and their relationships to other terms supported by literature references. The two modes of BEERE search analysis may be performed independently, simultaneously or sequentially (as we show in the case study). When performed simultaneously, users with a mixture of gene and other entity terms may search at least the subset of input list containing genes only using both input modes to compare the resulting relative rank and network context information constructed from the protein-protein interaction knowledgebase (for gene input mode) and the PubMed literature (for term input mode). BEERE enables users to search for semantic relationships based on specific categories including gene-drug, gene-disease, drug-gene or drug-disease relationships, using intuitive web graphical user interfaces, tables, charts and network graphs. We expect BEERE to become a useful web server in biomedical entity network exploratory analysis and hypothesis generations.

MATERIALS AND METHODS

Entity-to-entity association data sources and pre-processing

We downloaded protein–protein interaction (PPI) data from the HAPPI 2.0 database (16), which included 2,922,202 quality-ranked PPI data from both experimental and computational platforms its 2017 release. HAPPI database is a quality-ranked comprehensive PPI repository that uses 'H-score'—a probabilistic score between 0 and 1 to express any PPI as true and reliable (16)—control data quality versus coverage tradeoffs. In BEERE, we set the minimal quality of reported PPI data to be at the '3-star grade' and above to achieve a proper balance between data coverage and quality. This filter allows us to retain ~22% of all the downloaded PPIs.

We downloaded Subject-Predicate-Object triples called predications to represent known semantic relationships between biomedical entities from the SemMedDB version 31_R (updated on 30 June 2018) (30), which contained 19,836,578 unique predications extracted from PubMed. SemMedDB uses SemRep (31), a natural language processing engine, to scan PubMed article titles and abstracts, extract semantic information from biomedical text, and map extracted Subjects-Predictes-Objects to UMLS standard vocabularies wherever applicable. In BEERE, we quantitatively evaluate each semantic relationship between a Subject and an Object using a statistical test based on a hypergeometric distribution model. The test works by assessing the statistical significance of observing a specific count of PubMed citations that support a given Subjectto-Object pair for each Predicate category against a background distribution. We then calculate a Relation Density Score (RDS) for each Subject-to-Object relationship, based on the P-value derived from each statistical significance test performed (for details, refer to Supplementary Data). In all, 18,376,458 out of all 19,836,578 predications have a calculated RDS score > 0.

Biomedical entity identification and expansion

We downloaded standard gene symbol and gene alias information from the NCBI Gene database to resolve gene symbol entries in the gene input mode. In the term input mode, we standardize all input biomedical terms to the term dictionary compiled by the SemMedDB. However, gene name entity recognition in the SemMedDB is not always accurate, even though gene symbols and gene IDs are standardized. For example, we found that the 'ENO1' term (CUI = 2023) and the 'ENO1 gene' term (CUI = C1414402) were kept separate from each other in the SemMedDB, but they refer to the same semantic concept. Ongoing work of using both NCBI gene thesaurus and gene ontology to map and resolve gene entities is still needed. For the same reason, we are keeping the gene input mode separate from the term input mode in the current implementation of BEERE.

To map input biomedical terms to those represented in the SemMedDB term dictionary, we provide three userselected term matching strategies: 'exact match', 'substring match' and 'fuzzy match'. An exact match requires the user input term to match exactly an entry in the SemMedDB term dictionary. BEERE chooses this option by default. A substring match requires the user input term to match a term in the SemMedDB term dictionary using a regular expression match to the closest term by length. A fuzzy match utilizes the Levenshtein-distance (L-distance) function in the Oracle database to retrieve all candidate terms. Since the term semantics can be heavily altered by a deletion or a replacement of characters in a term, we set the penalty score of deletion or replacement to be 5, higher than the penalty score of insertion at 1. BEERE returns the term with the lowest L-distance as the best match and users have the option of overriding this by selecting more than one best match in the advanced mode.

Network data quality control

To quantitively evaluate the network's quality before the biomedical entity ranking, BEERE introduces two metrics: index of aggregation (IOA) and seed's coverage in the network (SCN). IOA assumes that the network possessing high quality will contain as much as connected nodes in the largest network. IOA is calculated using the number of the nodes in the largest network divided by the total input. SCN is a broad aggregation index that assumes that the higher quality network, the higher connected nodes than isolated nodes. SCN is calculated by the number of connected nodes divided by the total input.

Network-based entity prioritization

BEERE provides an initial ranking algorithm and two iterative ranking algorithms. The initial ranking algorithm applies a heuristic relevance score calculation developed in (1). The relevance score calculation is a fast evaluation of the hub nodes by involving the weighted neighborhood and it successfully ranks the top biological relevant genes in Alzheimer's disease. The two iterative ranking algorithms, PageRank and ant-colony algorithm, are widely used in different knowledge domains with considerable successful applications. We describe the full details of PageRank, modified ant-colony algorithm and the statistical evaluation in BEERE ranking in the Supplementary Data.

Network visualization and annotation

word-cloud visualization (https://github.com/ The timdream/wordcloud2.js/) of the entity ranking is implemented in BEERE. The biomedical entity font size in word-cloud is generated based on the square-root of the ranking score divided by the square root of the total entity's number and multiplied by a scale factor. The default scale factor is set to be 40. The histogram visualization of the ranking score distribution is supported by d3.js. The bin size of the distribution is the log2-scale ranking score. The sigma.js (http://sigmajs.org/) javascript is implemented to visualize the network. The enhanced network visualization features, such as draggable nodes, hover effect, color grouping, clickable nodes and edges, and layout algorithms, are supported by the modified plugins from sigma.js adapted to BEERE.

Data provenance

Both PPI data provenance and term-to-term association data provenance are managed in BEERE. We manage PPI data provenance from both the HAPPI 2.0 database download and the PubTator (32) results. In the gene annotation, PubTator reports F1 scores as 82.97 using the GeneTUKit and 92.89 using the GenNorm. HAPPI 2.0 databases contain reference sources of all compiled PPIs, which we compiled into the BEERE web server. Pubtator applies text mining technique to process all PubMed articles (both titles and abstracts) into a gene2Pub file, while also compiled into BEERE. The 09/2018 version that we incorporated into BEERE contained 7,677,876 gene-to-PMID relationship pairs, where PMID refers to the PubMed article identifier. We manage predication data provenance directly using 96,363,098 predication-to-PMID PubMed text citations in the SemMedDB version 31 R.

Web server design and data management architecture

We developed BEERE as an integrated, searchable, knowledge-based web server. BEERE was developed using PHP5, Javascript and an open-source CodeIgniter infrastructure developed by EllisLab (https://www.codeigniter. com/). The ranking algorithms and statistical analysis in BEERE are written in python 3.0. The algorithms are optimized by parallel processing and the application programming interface (API) service is supported by Django (https://github.com/django/django). DataTables (https://datatables.net/), a plugin for jQuery is used for displaying the tables, a plugin for jQuery was used for displaying the tables. Oracle Database 12g (https://www.oracle. com/database/12g-database/) is used in the database server. The compatibility of BEERE is shown in the help session online.

RESULTS

Summary of features

The pages of BEERE consist of three components: main body, left sidebar and right sidebar. The main body returns the intermediate/final table or graphs. The left sidebar is used for displaying the parameter panel or advanced input in advanced mode, and the right sidebar is used to show additional details such as data provenance during network exploratory analysis sessions.

BEERE offers advances to the other popular web servers such as ToppGene (4), Phenolyzer (23) and Semantic MED-LINE (33), by implementing several advanced features. We summarize the contribution of BEERE with respect to algorithms, data and quality control, and the visualization shown in Table 1. Given the input of fewer than 1000 entities, BEERE will return reasonable respective interactivity within the limited time using parallel processing and the iterative ranking algorithms in BEERE capture preference of the given item versus all of the others, not just immediate neighbors. The quality control of PPI and the biomedical term-to-term relationships enable the users to expand the seed to a certain extent. The network expansion allows BEERE to increase the index of aggregation by introducing

Feature		BEERE	ToppGene	Phenolyzer	Semantic MEDLINE
Algorithm	Ranking algorithm	PageRank, ant-colony	k-step Markov, PageRank, HITS	Gene-disease score	Not mention
	Iterative ranking	yes	yes	no	no
Evaluation	Statistical model	yes	yes	no	no
Data and quality	Relationship quality control	yes	no	yes (factor control)	no
	Network extension with IOA evaluation	yes	yes (neighbor distance)	no	no
	Biomedical term	yes	no	yes (disease)	yes
Visualization	Network with provenance data	yes	yes (provide networks)	yes	yes
	Grouping annotation	yes	no	no	no

Table 1. The features comparison between BEERE and other three web servers: ToppGene, Phenolyzer and Semantic Medline

Grouping annotation: The node color visualization using the annotation, e.g the genes annotated in different pathways can be visualized in the network using different colors.

the 'bridge' nodes that connect to at least two seeds. Therefore, BEERE can monitor the network quality and seed's coverage in quantitive quality control. The biomedical term and term-to-term relationships have been introduced in the BEERE, which can be a huge interest to the hypothesisdriven analysis. The network with detail information in the visualization panel provides an intuitive way for the users to grasp the critical biomedical entities. More features such as entity grouping annotation and layout algorithm options enable the users to easily observe new biomedical entity patterns in the network.

Given a list of biomedical entities, BEERE provides a five-step procedure to generate the biomedical rank and visualization panels shown in the 'Graphical abstract'.

Searching the databases with a list of terms or genes

The input page allows users to enter a gene list or a biomedical term list, and BEERE will retrieve the matched entity and relationships from the databases HAPPI 2.0 and SemMedDB respectively. We use two as examples. One is a gene list consisting of 200 glioblastoma (GBM) genetic candidates from the OMIM database. The other is a term list consisting of three different vitamins and Alzheimer's disease. The advanced parameters setting allows users to control relationships quality. In PPI retrieval, the parameter 'PPI confidence' provides three PPI cutoffs '0.45', '0.75' and '0.9' and a 'customized cutoff' option. Those three PPI cutoffs are equivalent to the 3-star, 4-star and 5-star PPI's quality in the HAPPI 2.0 database. In the term-to-term relationship retrieval, users can enter a number varied from 0 to max-value of the RDS. The parameter 'expanded' provides the option for network one-layer expansion, which potentially increases the index of aggregation by introducing the 'bridge' nodes to the network. In biomedical term retrieval, the parameter 'matching' offers 'fuzzy matching', 'substring matching' and 'exact matching' options to maximize the retrieving power. The parameter 'predicate' provides a list of predicates for a single or multiple selections.

Verifying retrieved terms against search terms

The retrieved biomedical entity page helps the user to verify the query. In the matched entity table, the matches and mismatches are displayed for users to review and search again. In the example of a gene list, the gene matching table shows the queried gene symbols, matched gene and Seed/Expanded/none tag 'S/E/-'. If the user's input gene is an alias or a gene synonym, BEERE will automatically map the queried gene to HAPPI 2.0 database gene symbols. In the example of a term list using 'substring' matching, the table shows matches and modified matches with the lowest Levenshtein's distance (L-distance) as the best candidates. In the advanced model, all the potential mismatches are displayed for an adjustment.

Retrieving known relationships

In the retrieved related relationships page, the relationships table shows the quality of the relationships. Reviewing the two tables, users can choose to 'refine the table and try to match again' or 'process to entity prioritization'. In advanced search, users can adjust the parameters 'iteration', 'sigma' and 'method.' The parameter 'iteration' provides the recursive ranking score. The parameter 'method' provides the 'page rank' and 'ant colony' algorithms. The parameter 'sigma' provide a damping factor varying from [0,1] (default value is 0.8), which determines the probability of randomly choosing a relationship will eventually stop choosing.

Rank entities from the network

The biomedical entity prioritization page provides the table and two visualization panels. In the prioritization table, there are six parameters: 'entity name', 'in-expanded network', 'ranking score', 'rank', 'adjust *P*-value' and 'significance'. Each row is clickable and it is linked to the entity information page. The page shows the attributes of the biomedical entity and the relationships specific to the selected entity. In the visualization panels, two graphic figures help users to intuitively view the significant entities and the ranking score distribution. The word-cloud graph deploys the highly significant biomedical entities in the center with relative larger fonts.

Expanded	Yes (0.9)		No			
PPI Cutoff	0.9	0.45	0.75	0.9		
IOA	0.99 (1962/1984)	0.76 (130/172)	0.64 (110/172)	0.52 (90/172)		
SCN	0.87 (150/172)	0.78 (134/172)	0.68 (117/172)	0.59 (102/172)		
Interaction	6833	543	326	200		

Table 2. The network quality control using different PPI cutoffs

IOA: Index of Aggregation, SCN: Seed's Candidate Coverage in Network

Visual exploration of network relationship data

The network visualization page provides an interactive graphical panel to allow users intuitively to discover the critical entities and interactions with provenance. Three layout algorithms, directed-force (default), DEMA and circular have been provided. The current view of the network can be exported as a PNG image and the network's edge and node information can be exported as an SVG file. The left side advanced function panel offers a customized entity association input for adding the grouping information, and by clicking 'next' button, BEERE visualizes the color-grouped nodes in the network graph. The edges are clickable that can trigger the right side panel and show the table of entity relationship's detail and the provenance of the relationships.

CASE STUDY

While BEERE supports user analysis with either 'a gene list as the input' or 'a term list as the input' independently, we will demonstrate a more sophisticated case study in which genes and terms are analyzed in conjunction with each other. In this case study, a user is presumably interested in exploring all candidate genes for glioblastoma (GBM), an aggressive form of brain tumor with low patient survival, to understand which genes may be worth validating experimentally and whether there are additional candidate genes not yet curated in public databases.

To prepare the BEERE web-based data analysis, a BEERE user first performs a search for disease-specific candidate genes against the NCBI-hosted OMIM database (34), which contains disease-gene curations for more than 6300 disease phenotypes and more than 4000 genes. Upon search with the term 'glioblastoma', the OMIM database returned 241 entries, among which 200 are gene candidates. The user then saves the gene list ('seed genes' or the 'seed') to perform a 'gene list as the input' query against the BEERE web server (refer to Example B on the web server to obtain this gene list). Since the user is also interested in finding new gene candidates, user can set the network expansion flag as 'YES', using HAPPI 2.0 PPI data with the quality filter of 0.75 (four-star ratings) and above.

After a user confirms the mapping of matched gene symbols in the BEERE's database, BEERE shows (in step third) a list all the seed genes and network-expanded genes using the nearest neighbor network consisting of PPIs from the HAPPI 2.0 database, default PPI quality control parameters and the default gene ranking algorithm. The expanded gene network has a high IOA at 99% and seed gene coverage in the network (SCN) is 87% (Table 2). The result shows that seed gene ranking remains consistent regardless

of whether there is an expanded network or not, because top-10 BEERE-ranked seed genes in the expanded network are also found in the top 10% in non-expanded network, except for PLK1 (Table 3). The entire gene rank of the expanded and non-expanded networks are shown in Supplementary Tables S1–4. The PLK1 ranks in the top due to its high connectivity to the expanded genes. About 250 out of 258 PLK's interactors are expanded genes. Three of those expanded genes, UBC, APP and MYC, are statistically significant with *P*-values < 0.05. Meanwhile, these genes are also reported to be ubiquitously expressed in brain (35). PLK1 is a Ser/Thr protein kinase gene belonging to the CDC5/Polo subfamily. It is highly expressed during mitosis and elevated levels of PLK1 are found in many cancers including glioblastoma (36.37). About 14 expanded genes are statistically significant at *P*-values <0.05 (Figure 1). All 14 genes except for the EGF gene, a gene with more than 384 PubMed abstract co-citations with the term 'glioblastoma', are also ranked by ToppGene in the top 5.5% (Table 4). Our BEERE results also highlighted the significance of performing biological entity expansions—expanding gene symbols to aliases and gene full names-to reduce false negatives.

To investigate whether the 'new' candidate genes discovered from BEERE gene-based analysis is valid, a user may continue the web-based analysis by switching to BEERE term-based analysis section, using terms including 'glioblastoma' and each of the 14 new candidate genes. After term expansion and ranking, BEERE helps users to construct a network in the last analysis step (step fifth) to allow users' visual exploration of the heterogeneous biomedical entity-to-entity interaction network, which consists of both disease terms and gene symbols. BEERE-generated semantic predications help users to validate co-cited geneto-disease pairs (Table 4) given the options of SemMed V30 and 'fuzzy matching'. BEERE-generated ranks of the biomedical terms reveal that the epidermal growth factors, amyloid genes, ubiquitin genes and tyrosine genes are tightly related to glioblastoma. Further, exploring each candidate gene's mechanisms of actions in glioblastoma shows that 11 out of 14 genes have a direct effect on glioblastoma. Among them, five genes (UBC, MYC, HDAC1, SUMO1 and ABL1) augment glioblastoma; four genes (APP, SRC, FYN and EP300) are associated with glioblastoma; a gene (EGF) and an estrogen receptor (ESR1) produce the glioblastoma (38,39). All the above relationships can be explored within the network visually and shown in the detailed HTML tables next to the network graph on the web server to reveal underlying PubMed articles referred by the predications. Interestingly, among the three genes (CREBBP, PCNA, ESR1) without direct relationships found within SemMedDB extracted predications,



Figure 1. The pipeline overview of the conjunction analysis in glioblastoma (GBM) genetic candidate's discovery. In the first part, BEERE offers a ranked order list of critical seed and expanded genes with statistical significance using the expanded network analysis. (A) The input is the 200 genetic candidate genes downloaded from OMIM databases. (B) In BEERE quality control, BEERE automatically maps the queried genes to HAPPI database gene symbols. By verifying the 172 genes matched to HAPPI database, BEERE returns 6833 PPIs passing the PPI cutoff. The network quality is good that Index of Aggregation = 0.99 and Seed's Coverage in Network = 0.87. (C) BEERE generates the gene ranks. About 87 seed genes are statistically significant and 14 expanded genes are statistically significant. In the second part, BEERE reveals the critical mechanisms using comprehensive term mapping, heterogeneous network analysis, and term ranking. (D) About 28 biomedical entities using genes, aliases and disease terms are the input of the network meta-analysis. (E) The term ranking score distribution and term rank word-cloud intuitively show the important entities using growth factors, amyloid genes, ubiquitin genes and tyrosine genes are tightly related to glioblastoma. The provenance of the gene to glioblastoma relationship is displayed on the selected edge such as APP affects glioblastoma with one literature support. The PMID and a link to outsource are displayed by clicking the entry with the detail of the relationships.

Table 3.	The top-10 ranked seed	genes in expa	anded network com	pared to the ranks in	n non-expanded networks
	1			1	1

	5-star+Exp.			3-star		4-star	5-star	
Seed Gene	Rank	P-value	Rank	<i>P</i> -value	Rank	<i>P</i> -value	Rank	P-value
TP53	1	0.00053	2	0.015	2	0.017	4	0.0028
EGFR	2	0.0011	4	0.03	4	0.034	5	0.0032
PIK3R1	3	0.0016	5	0.037	3	0.026	2	0.0012
AKT1	4	0.0021	3	0.022	6	0.051	8	0.0085
CTNNB1	5	0.0027	1	0.0075	1	0.0085	1	0.00096
PIK3CA	6	0.0032	9	0.067	5	0.043	3	0.0027
PLK1	7	0.0037	31	0.23	21	0.18	12	0.036
RAC1	8	0.0043	11	0.082	10	0.085	6	0.0053
RB1	9	0.0048	10	0.075	9	0.077	7	0.0065
CCND1	10	0.0053	7	0.052	7	0.06	11	0.019

Gene	Search term	BEERE Top rank	<i>P</i> -value	ToppGene rank	ToppGene Normal- ized rank	PubMed Initial count	PubMed Extended count	Network validation	Literatures	PMID
UBC	UBC or ubiquitin or ubiquitin C	1 (33)	0.017	116	32	0	137	Augments	1	27766591
APP	APP or amyloid or amyloid beta	2 (54)	0.028	1	1	23	61	Affects	1	15302999
MYC	MYC or c-myc or myc proto-oncogene	3 (69)	0.035	17	5	300	300	Augments	1	26993778
HDAC1	HDAC1 or Histone decacetylase	4 (74)	0.038	46	13	12	12	Augments	1	27766591
SUMO1	SUMO1 or ubiquitin	5 (75)	0.038	373	102	3	138	Augments	1	27766591
SRC	SRC or Tyrosine-Protein Kinase	6 (76)	0.039	31	9	165	167	Affects	6	3146045 15994925 15618223 20947248 19098899 25048528
ABL1	ABL1 or Tyrosine-Protein Kinase	7 (83)	0.042	142	39	4	10	Augments	1	23383209
FYN	FYN or Tyrosine-protein kinase	8 (85)	0.043	93	26	17	23	Affects	1	15994925
PCNA	PCNA or Proliferating Cell Nuclear Antigen	9 (87)	0.044	166	45	93	108	Indirectly affect	-	-
EP300	EP300 or E1A Binding Protein P300	10 (88)	0.045	52	15	3	5	Affects	2	21489305126722247
GRB2	GRB2 or Growth Factor Receptor Bound Protein	11 (90)	0.046	22	6	14	14	Indirectly affect	-	-
CREBBP	CREBBP or CREB Binding Protein	12 (92)	0.047	83	23	1	4	Indirectly affect	-	-
EGF	EGF or Epidermal Growth Factor	13 (93)	0.047	5146	1395	384	1419	Produces	1	3011820
ESR1	ESR1 or Estrogen Receptor 1	14 (96)	0.049	34	10	5	6	Produces	1	20841389

Table 4.	The expanded genes	validation using the F	ubMed article term-	to-term co-citations	and network semanti	c relationship validation
----------	--------------------	------------------------	---------------------	----------------------	---------------------	---------------------------

each gene connects to six (for CREBBP), seven (for PCNA) and six (for ESR1) existing genes, respectively. This suggests strong candidacy for these genes were investigated further for their molecular mechanism links to glioblastoma.

Furthermore, we believe the case study above demonstrated that BEERE not only as a tool for gene-based or term-based network expansion, ranking and exploration tools separately, but also as an iterative analysis platform for users who switch between biomedical entity relationship explorations and phenotypically significant gene network explorations. For example, having obtained the above results, a user may enter into 'gene-based' analysis again, using 200 previously OMIM-curated genes and 14 newly discovered candidate genes, to explore a gene-to-gene association network without network expansions. Such ranking may shed additional light on the relative significance of all candidate genes. Networks using disease, genes and drugs may also be expanded, ranked and explored iteratively from within the BEERE tool subsequently.

DISCUSSION

BEERE is a new web-based data analysis tool to help biomedical researchers characterize any input list of genes/proteins, biomedical terms, or their combinations against databases containing gene-to-gene relationships and semantic term-to-term relationships. We developed

BEERE first to help users examine whether there is credible biological evidence of gene-to-gene associative relationships or term-to-term semantic relationships within the user input of a gene/term list. This is an important first step towards the interpretation of high-throughput Omics sequencing data or manually curated biological entities for hypothesis-driven research. Moreover, using the entire collection of biomedical entity-to-entity relationship pairs, we demonstrated that BEERE can help users uncover the inherent relative importance of each entity within the list, allow users to visually explore constructed global entity relationship network and assist users with examining different types of relationship pairs to trace back biomedical entity relationships of interest to the original cited PubMed articles. We demonstrated that BEERE could accelerate biomedical mechanistic studies downstream of Omics analysis or initial curation with its current set of features when proper parameters are set correctly. We envision biological users of BEERE could use the entity expansion, ranking and exploration features iteratively to examine geneto-gene, gene-to-disease, gene-to-drug, gene-to-risk factors, and many types of biomedical entity relationships for their research. With ongoing database update and database coverage expansion to include additional contents from sources such as gene sets and gene signatures, e.g., PAGER (40) and GeneSigDB (41), we expect BEERE to become a useful web service for the biomedical research community.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

FUNDING

University of Alabama at Birmingham (UAB) Informatics Institute; UAB Academic Enrichment Fund (to J.C.); Center for Clinical and Translational Science of the University of Alabama at Birmingham [1TL1TR001418–01 to J.C.]; National Center for the Advancement of Translational Science (NCATS); National Cancer Institute [U01CA223976 to J.C., C.D.W., A.B.H.)]. Source of open access charge: University of Alabama at Birmingham (UAB) Informatics Institute; UAB Academic Enrichment Fund (to J.C.); Center for Clinical and Translational Science of the University of Alabama at Birmingham [1TL1TR001418–01 to J.C.]; National Center for the Advancement of Translational Science (NCATS); National Cancer Institute [U01CA223976 to J.C., C.D.W., A.B.H.)].

Conflict of interest statement. None declared.

REFERENCES

- Chen,J.Y., Shen,C. and Sivachenko,A.Y. (2006) Mining Alzheimer disease relevant proteins from integrated protein interactome data. *Pac. Symp. Biocomput.*, 11, 367–378.
- 2. Guala, D. and Sonnhammer, E.L.L. (2017) A large-scale benchmark of gene prioritization methods. *Sci. Rep.*, **7**, 46598.
- Nitsch, D., Tranchevent, L.C., Goncalves, J.P., Vogt, J.K., Madeira, S.C. and Moreau, Y. (2011) PINTA: a web server for network-based gene prioritization from expression data. *Nucleic Acids Res.*, 39, W334–W338.
- Chen, J., Bardes, E.E., Aronow, B.J. and Jegga, A.G. (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.*, 37, W305–W311.
- Adie,E.A., Adams,R.R., Evans,K.L., Porteous,D.J. and Pickard,B.S. (2006) SUSPECTS: enabling fast and effective prioritization of positional candidates. *Bioinformatics*, 22, 773–774.
- Yu,W., Wulf,A., Liu,T., Khoury,M.J. and Gwinn,M. (2008) Gene Prospector: an evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. *BMC Bioinformatics*, 9, 528.
- Tranchevent, L.C., Barriot, R., Yu, S., Van Vooren, S., Van Loo, P., Coessens, B., De Moor, B., Aerts, S. and Moreau, Y. (2008) ENDEAVOUR update: a web resource for gene prioritization in multiple species. *Nucleic Acids Res.*, 36, W377–W384.
- Lupski, J.R., Reid, J.G., Gonzaga-Jauregui, C., Rio Deiros, D., Chen, D.C., Nazareth, L., Bainbridge, M., Dinh, H., Jing, C., Wheeler, D.A. *et al.* (2010) Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. *N. Engl. J. Med.*, 362, 1181–1191.
- Doncheva, N.T., Kacprowski, T. and Albrecht, M. (2012) Recent approaches to the prioritization of candidate disease genes. *Wiley Interdiscip. Rev. Syst. Biol. Med.*, 4, 429–442.
- Bornigen, D., Tranchevent, L.C., Bonachela-Capdevila, F., Devriendt, K., De Moor, B., De Causmaecker, P. and Moreau, Y. (2012) An unbiased evaluation of gene prioritization tools. *Bioinformatics*, 28, 3081–3088.
- Moreau, Y. and Tranchevent, L.C. (2012) Computational tools for prioritizing candidate genes: boosting disease gene discovery. *Nat. Rev. Genet.*, 13, 523–536.
- Oti, M., Ballouz, S. and Wouters, M.A. (2011) Web tools for the prioritization of candidate disease genes. *Methods Mol. Biol.*, 760, 189–206.
- Piro,R.M. and Di Cunto,F. (2012) Computational approaches to disease-gene prediction: rationale, classification and successes. *FEBS J.*, **279**, 678–696.

- Tranchevent, L.C., Capdevila, F.B., Nitsch, D., De Moor, B., De Causmaecker, P. and Moreau, Y. (2011) A guide to web tools to prioritize candidate genes. *Brief Bioinform.*, 12, 22–32.
- Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P. *et al.* (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.*, 45, D362–D368.
- 16. Chen, J.Y., Pandey, R. and Nguyen, T.M. (2017) HAPPI-2: a comprehensive and high-quality map of human annotated and predicted protein interactions. *BMC Genomics*, **18**, 182.
- 17. Isik,Z., Baldow,C., Cannistraci,C.V. and Schroeder,M. (2015) Drug target prioritization by perturbed gene expression and network information. *Sci. Rep.*, **5**, 17417.
- Sivachenko, A.Y. and Yuryev, A. (2007) Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. *Expert Opin. Ther. Targets*, 11, 411–421.
- Yue,Z., Arora,I., Zhang,E.Y., Laufer,V., Bridges,S.L. and Chen,J.Y. (2017) Repositioning drugs by targeting network modules: a Parkinson's disease case study. *BMC Bioinformatics*, 18, 532.
- Denecke,K. (2008) Semantic structuring of and information extraction from medical documents using the UMLS. *Methods Inf. Med.*, 47, 425–434.
- Burger, G., Abu-Hanna, A., de Keizer, N. and Cornet, R. (2016) Natural language processing in pathology: a scoping review. *J. Clin. Pathol.*, 69, 949–955.
- Matthies, F. and Hahn, U. (2017) Scholarly information extraction is going to make a quantum leap with pubmed central (PMC). *Stud. Health Technol. Inform.*, 245, 521–525.
- Yang,H., Robinson,P.N. and Wang,K. (2015) Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. *Nat Methods*, **12**, 841–843.
- Song,Y., Kim,E., Lee,G.G. and Yi,B.K. (2005) POSBIOTM-NER: a trainable biomedical named-entity recognition system. *Bioinformatics*, 21, 2794–2796.
- Wang, X., Zhang, Y., Ren, X., Zhang, Y., Zitnik, M., Shang, J., Langlotz, C. and Han, J. (2018) Cross-type biomedical named entity recognition with deep multi-task learning. *Bioinformatics*, 35, 1745–1752.
- Zhao,Z., Yang,Z., Luo,L., Wang,L., Zhang,Y., Lin,H. and Wang,J. (2017) Disease named entity recognition from biomedical literature using a novel convolutional neural network. *BMC Med. Genomics*, 10, 73.
- Lee, S., Kim, D., Lee, K., Choi, J., Kim, S., Jeon, M., Lim, S., Choi, D., Kim, S., Tan, A.C. *et al.* (2016) BEST: next-generation biomedical entity search tool for knowledge discovery from biomedical literature. *PLoS One*, **11**, e0164680.
- Brown,G.R., Hem,V., Katz,K.S., Ovetsky,M., Wallin,C., Ermolaeva,O., Tolstoy,I., Tatusova,T., Pruitt,K.D., Maglott,D.R. *et al.* (2015) Gene: a gene-centered information resource at NCBI. *Nucleic Acids Res.*, 43, D36–D42.
- McInnes, B.T., Pedersen, T. and Carlis, J. (2007) Using UMLS Concept Unique Identifiers (CUIs) for word sense disambiguation in the biomedical domain. *AMIA Annu. Symp. Proc.*, 2007, 533–537.
- Kilicoglu, H., Shin, D., Fiszman, M., Rosemblat, G. and Rindflesch, T.C. (2012) SemMedDB: a PubMed-scale repository of biomedical semantic predications. *Bioinformatics*, 28, 3158–3160.
- Liu, Y., Bill, R., Fiszman, M., Rindflesch, T., Pedersen, T., Melton, G.B. and Pakhomov, S.V. (2012) Using SemRep to label semantic relations extracted from clinical text. *AMIA Annu. Symp. Proc.*, 2012, 587–595.
- Wei,C.H., Kao,H.Y. and Lu,Z. (2013) PubTator: a web-based text mining tool for assisting biocuration. *Nucleic Acids Res.*, 41, W518–W522.
- 33. Cairelli, M.J., Miller, C.M., Fiszman, M., Workman, T.E. and Rindflesch, T.C. (2013) Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox. *AMIA Annu. Symp. Proc.*, 2013, 164–173.
- Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F. and Hamosh, A. (2015) OMIM.org: online mendelian inheritance in man (OMIM(R)), an online catalog of human genes and genetic disorders. *Nucleic Acids Res.*, 43, D789–D798.

- Fishilevich, S., Zimmerman, S., Kohn, A., Iny Stein, T., Olender, T., Kolker, E., Safran, M. and Lancet, D. (2016) Genic insights from integrated human proteomics in GeneCards. *Database*, 2016, baw030.
- Lerner, R.G., Grossauer, S., Kadkhodaei, B., Meyers, I., Sidorov, M., Koeck, K., Hashizume, R., Ozawa, T., Phillips, J.J., Berger, M.S. et al. (2015) Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells. *Cancer Res*, 75, 5355–5366.
- 37. O'Leary,N.A., Wright,M.W., Brister,J.R., Ciufo,S., Haddad,D., McVeigh,R., Rajput,B., Robbertse,B., Smith-White,B., Ako-Adjei,D. *et al.* (2016) Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.*, 44, D733–D745.
- Liu, J., Sareddy, G.R., Zhou, M., Viswanadhapalli, S., Li, X., Lai, Z., Tekmal, R.R., Brenner, A. and Vadlamudi, R.K. (2018) Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression. *Cancer Res.*, 78, 3176–3189.
- 39. Yang, W., Warrington, N.M., Taylor, S.J., Whitmire, P., Carrasco, E., Singleton, K.W., Wu, N., Lathia, J.D., Berens, M.E., Kim, A.H. *et al.* (2019) Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. *Sci. Transl. Med.*, **11**, eaao5253.
- Yue,Z., Zheng,Q., Neylon,M.T., Yoo,M., Shin,J., Zhao,Z., Tan,A.C. and Chen,J.Y. (2018) PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology. *Nucleic Acids Res.*, 46, D668–D676.
- Culhane, A.C., Schroder, M.S., Sultana, R., Picard, S.C., Martinelli, E.N., Kelly, C., Haibe-Kains, B., Kapushesky, M., St Pierre, A.A., Flahive, W. et al. (2012) GeneSigDB: a manually curated database and resource for analysis of gene expression signatures. *Nucleic Acids Res.*, 40, D1060–D1066.